Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative, Psychiatric, and Chronic Pain Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GRM5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRM5 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Suitable for Venus Flytrap Domain (VFTD) targeting. |
View GRM5 Products |
| Gene Delivery | GRM5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for functional Calcium Flux and IP-One assays. |
View GRM5 Products |
| Benchmark Ab | Anti-GRM5 (Sequence of Clinical/Research Leads) Recombinant positive control antibody for binding and validation. |
View GRM5 Products |
| Validator | GRM5 siRNA Set For knockdown verification in primary neurons or cell lines. |
View GRM5 Products |
| Related Target A | GRM1 (mGluR1) Crucial counter-screening target. High structural homology; off-target mGluR1 inhibition leads to motor ataxia. |
View GRM1 Products |
| Related Target B | GRM2 (mGluR2) Subfamily selectivity screening to verify allosteric modulator specificity. |
View GRM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent screening of GPCR | High-titer Lentivirus Premade Particles for stable cell line generation, preserving native 7-TM structure. |
| Subfamily off-target counter-screening (mGluR1) | Sequence-verified GRM1 and GRM5 recombinant extracellular domains (ECD) with native glycosylation. |
| Lack of Controls | Recombinant Benchmark Antibodies included for binding and functional assays. |
| False Positives | Validated siRNA sets included for target specificity verification. |
Live GRM5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development targeting metabotropic glutamate receptor 5 (GRM5/mGluR5) is undergoing a major renaissance. Historically studied for Fragile X syndrome, the focus has shifted toward Treatment-Resistant Depression (TRD), Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID), schizophrenia, and chronic pain. Because GRM5 is a Class C GPCR, drug discovery has moved away from orthosteric ligands toward Negative Allosteric Modulators (NAMs) and Positive Allosteric Modulators (PAMs) to achieve fine-tuned rheostat control of glutamatergic transmission without excitotoxicity.
"The race for GRM5 therapeutics is intensifying, with major players shifting focus from traditional small molecules to highly selective, brain-penetrant allosteric modulators and novel biologics targeting the extracellular domain. As first-generation therapies reach the clinic, the next wave of R&D is targeting structural selectivity over mGluR1 to eliminate motor side effects."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (NAM) | Addex Therapeutics, Novartis, Roche | PD-LID, Treatment-Resistant Depression | Functional assay development (Lentivirus-driven stable cell lines for Calcium Flux). |
| Small Molecule (PAM) | Janssen, Vanderbilt University | Schizophrenia, Cognitive Deficits | High-throughput screening (Stable cell line validation of positive cooperativity). |
| Monoclonal Antibodies / Nanobodies | Academic Institutes, Emerging Biotechs | Neuroinflammation, Chronic Pain | Extracellular Domain (ECD-Fc) binding assays with high-purity recombinant proteins. |